Q32 Bio (QTTB) Restructuring Costs (2023)

Q32 Bio (QTTB) recorded quarterly Restructuring Costs of $2.7 million in Q4 2023, down 59.53% quarter-over-quarter from $6.6 million in Q3 2023.

Q32 Bio (QTTB) Restructuring Costs (2023) Analysis & Trends

Q32 Bio's Restructuring Costs history runs 1 years deep, the most recent figure standing at $2.7 million for Q4 2023.

In Q4 2023, Restructuring Costs changed N/A year-over-year to $2.7 million; the TTM figure through Dec 2023 stood at $9.3 million (changed N/A YoY), while the FY2023 annual figure was $9.3 million, changed N/A from the prior year.
Restructuring Costs was $2.7 million for Q4 2023 at Q32 Bio, down from $6.6 million in the prior quarter.
In the past five years, Restructuring Costs ranged from a high of $6.6 million in Q3 2023 to a low of $2.7 million in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Q32 Bio	167.59 Mn	116.84 Mn	-

Download Data

Date	Value
Dec 31, 2023	2.69 Mn
Sep 30, 2023	6.64 Mn